Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation.

Trial Profile

Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Aspirin (Primary) ; Clopidogrel (Primary)
  • Indications Stent thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTIDUAL
  • Most Recent Events

    • 12 Sep 2015 Results published in the European Heart Journal.
    • 03 Jun 2010 Actual initiation date added to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top